Imatinib (INN) marketed by Novartis as Gleevec (Canada South Africa and the USA) or Glivec (Australia Europe and Latin America) and sometimes referred to by its investigational name STI-571 is a tyrosine-kinase inhibitor used in the treatment of multiple cancers most notably Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML).
This page contains content from the copyrighted Wikipedia article "Imatinib"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
